Clinical-Epidemiological Profile and Health-Related Quality of Life of Women with Breast Cancer During Chemotherapy Treatment: Observational Study

• Autor(a) principal: Marinho, Pabliane Matias Lordelo
• Data de Publicação: 2022
• Outros Autores: Lima, Ricardo Barbosa, Santos, José Cleyton de Oliveira, Santos, Dayane Ketlyn da Cunha, Silva, Glebson Moura, Kameo, Simone Yuriko, Sawada, Namie Okino
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Revista Brasileira de Cancerologia (Online)
• Texto Completo: https://rbc.inca.gov.br/index.php/revista/article/view/3164
• topic: neoplasias da mama/epidemiologia; neoplasias da mama/tratamento farmacológico; qualidade de vida; saúde da mulher; breast neoplasms/epidemiology; breast neoplasms/drug therapy; quality of life; women's health; neoplasias da mama/epidemiologia; neoplasias da mama/tratamento farmacológico; qualidade de vida; saúde da mulher

Introduction: Breast cancer may affect different profiles of women worldwide. In addition, chemotherapy to treat breast neoplasms directly affects health-related quality of life. Objective: To describe the clinical-epidemiological profile and to compare the general and specific health-related quality of life of women with breast cancer during chemotherapy. Method: In an observational and prospective study, 140 women with breast cancer in northeastern Brazil were evaluated in the intermediate cycle and at the end of chemotherapy. Quality of life was assessed using a general instrument (EORTC-QLQ-C30) and a specific module (EORTC-QLQ-BR23). Data were compared with a paired non-parametric test, with a significance level of 5%. Results: Regarding the clinical-epidemiological profile, the median age was 50 years, 82.9% were black or mixed-race, and 95% lived in Sergipe, Brazil. In addition, 50.7% had no occupation, the median family income was one minimum wage, as well as the median of education was eight years of study and only 40.7% have completed high school. Considering the data from the C30 and BR23 questionnaires, it was observed that most items and scales worsened at the end of chemotherapy when compared to the intermediate cycle. Among the items and scales with significant differences, most had moderate or high effect sizes. Conclusion: It is possible to conclude that the clinical-epidemiological profile was unfavorable and chemotherapy reduced several aspects of the health-related quality of life of women with breast cancer.